On March 4, 2024, CytoMed Therapeutics Ltd announced a collaboration with Sengkang General Hospital to develop an injectable cartilage regeneration therapy using umbilical cord-derived stem cells. This project aims to assess the therapy's efficacy in treating cartilage diseases through animal studies and a Phase I clinical trial.